Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated Drug‐Drug Interactions Using In Vitro Assays and Real‐World Data

A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates

(2020) Susan Cole et al.   Drug Metabolism and Pharmacokinetics

Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP

(2020) Ling Zou et al.   MOLECULAR PHARMACEUTICS

A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29

(2020) S.P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardiovascular Toxicities Associated with Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database

(2020) Lee S. Nguyen et al.   CIRCULATION

Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment

(2020) Dan M. Roden et al.   CIRCULATION

Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment

(2020) Dan M. Roden et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy

(2020) JM. Scherrmann   AAPS Journal

2020 FDA Drug-Drug Interaction Guidance -Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists

(2020) Sirimas Sudsakorn et al.   CURRENT DRUG METABOLISM

Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives

(2020) Ling Zou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

(2020) Thibault Fiolet et al.   CLINICAL MICROBIOLOGY AND INFECTION

Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3

(2020) Ling Zou et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters

(2020) Johanna Weiss et al.   Pharmaceutics

Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects

(2019) Tomohisa Nakada et al.   Drug Metabolism and Pharmacokinetics

A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters

(2019) Peter Tatrai et al.   DRUG METABOLISM AND DISPOSITION

Organic Cation Transporters in Health and Disease

(2019) Hermann Koepsell   PHARMACOLOGICAL REVIEWS

Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity

(2018) Ling Zou et al.   MOLECULAR PHARMACOLOGY

Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases

(2018) Masahiro Kanai et al.   NATURE GENETICS

Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content

(2018) Xiaomin Liang et al.   PLOS BIOLOGY

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

(2018) Xiaoyan Chu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies

(2018) Andrew P. Morris et al.   Nature Communications

Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1)

(2017) Eugene C. Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function

(2016) Cristian Pattaro et al.   Nature Communications

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers

(2015) Kari M. Morrissey et al.   CLINICAL PHARMACOKINETICS

MatchIt: Nonparametric Preprocessing for Parametric Causal Inference

(2015) Daniel E. Ho et al.   Journal of Statistical Software

Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling

(2012) Matthias B. Wittwer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2

(2012) Atsushi Hosomi et al.   PLoS One

Decreased extra-renal urate excretion is a common cause of hyperuricemia

(2012) Kimiyoshi Ichida et al.   Nature Communications

Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics

(2011) Atsushi Yonezawa et al.   BRITISH JOURNAL OF PHARMACOLOGY

Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin

(2011) Divya Samineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Profiling of a Prescription Drug Library for Potential Renal Drug–Drug Interactions Mediated by the Organic Cation Transporter 2

(2011) Yasuto Kido et al.   JOURNAL OF MEDICINAL CHEMISTRY

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter

(2011) Pei-Rong Ding et al.   PLoS One

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study

(2009) Z-C Jing et al.   HEART

Genome-wide association meta-analysis for total serum bilirubin levels

(2009) A. D. Johnson et al.   HUMAN MOLECULAR GENETICS

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

(2008) Jennifer J Kiser et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES